These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 28272733)

  • 1. [An update on the pharmacological treatment of attention deficit hyperactivity disorder: lisdexamphetamine and extended-release guanfacine].
    Martin Fernandez-Mayoralas D; Fernandez-Perrone AL; Munoz-Jareno N; Fernandez-Jaen A
    Rev Neurol; 2017 Mar; 64(s02):S1-S8. PubMed ID: 28272733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the current data on guanfacine extended release for the treatment of ADHD in children and adolescents.
    Childress A; Hoo-Cardiel A; Lang P
    Expert Opin Pharmacother; 2020 Mar; 21(4):417-426. PubMed ID: 31971448
    [No Abstract]   [Full Text] [Related]  

  • 3. Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Childress AC
    Adv Ther; 2012 May; 29(5):385-400. PubMed ID: 22610723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is adjunctive pharmacotherapy in attention-deficit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHD.
    Lachaine J; Sikirica V; Mathurin K
    BMC Psychiatry; 2016 Jan; 16():11. PubMed ID: 26774811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guanfacine extended release: a novel treatment for attention-deficit/hyperactivity disorder in children and adolescents.
    Faraone SV; McBurnett K; Sallee FR; Steeber J; López FA
    Clin Ther; 2013 Nov; 35(11):1778-93. PubMed ID: 24139092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ▼Guanfacine for ADHD in children and adolescents.
    Drug Ther Bull; 2016 May; 54(5):56-60. PubMed ID: 27173784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents.
    Sikirica V; Haim Erder M; Xie J; Macaulay D; Diener M; Hodgkins P; Wu EQ
    Pharmacoeconomics; 2012 Aug; 30(8):e1-15. PubMed ID: 22788263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial.
    Hervas A; Huss M; Johnson M; McNicholas F; van Stralen J; Sreckovic S; Lyne A; Bloomfield R; Sikirica V; Robertson B
    Eur Neuropsychopharmacol; 2014 Dec; 24(12):1861-72. PubMed ID: 25453486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Attention-Deficit/Hyperactivity Disorder in Adolescents: A Systematic Review.
    Chan E; Fogler JM; Hammerness PG
    JAMA; 2016 May; 315(18):1997-2008. PubMed ID: 27163988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guanfacine for the treatment of attention deficit hyperactivity disorder in children and adolescents.
    Rizzo R; Martino D
    Expert Rev Neurother; 2015 Apr; 15(4):347-54. PubMed ID: 25800130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guanfacine ER for the treatment of adolescent attention-deficit/hyperactivity disorder.
    Bukstein OG; Head J
    Expert Opin Pharmacother; 2012 Oct; 13(15):2207-13. PubMed ID: 22957772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. α2-Adrenergic Agonists or Stimulants for Preschool-Age Children With Attention-Deficit/Hyperactivity Disorder.
    Harstad E; Shults J; Barbaresi W; Bax A; Cacia J; Deavenport-Saman A; Friedman S; LaRosa A; Loe IM; Mittal S; Tulio S; Vanderbilt D; Blum NJ
    JAMA; 2021 May; 325(20):2067-2075. PubMed ID: 33946100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration.
    Newcorn JH; Stein MA; Childress AC; Youcha S; White C; Enright G; Rubin J
    J Am Acad Child Adolesc Psychiatry; 2013 Sep; 52(9):921-30. PubMed ID: 23972694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcomes with medications for attention-deficit hyperactivity disorder: current status of knowledge.
    Huang YS; Tsai MH
    CNS Drugs; 2011 Jul; 25(7):539-54. PubMed ID: 21699268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guanfacine extended-release (intuniv) for ADHD.
    Med Lett Drugs Ther; 2010 Oct; 52(1349):82-3. PubMed ID: 21045757
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparative efficacy and tolerability of pharmacological interventions for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis.
    Cortese S; Adamo N; Mohr-Jensen C; Hayes AJ; Bhatti S; Carucci S; Del Giovane C; Atkinson LZ; Banaschewski T; Simonoff E; Zuddas A; Barbui C; Purgato M; Steinhausen HC; Shokraneh F; Xia J; Cipriani A; Coghill D;
    BMJ Open; 2017 Jan; 7(1):e013967. PubMed ID: 28073796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the treatment of attention-deficit/hyperactivity disorder: a guide for pediatric neurologists.
    Wigal SB; Chae S; Patel A; Steinberg-Epstein R
    Semin Pediatr Neurol; 2010 Dec; 17(4):230-6. PubMed ID: 21183129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Lisdexamfetamine dimesylate: a Treatment Option for Children and Adolescents with Attention Deficit/Hyperactivity Disorder in Germany and Across Europe].
    Häge A; Banaschewski T; Dittmann RW
    Fortschr Neurol Psychiatr; 2015 Dec; 83(12):676-85. PubMed ID: 26714249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of alpha2-adrenergic agonists in attention-deficit/hyperactivity disorder.
    Sallee FR
    Postgrad Med; 2010 Sep; 122(5):78-87. PubMed ID: 20861591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacotherapy for child and adolescent attention-deficit hyperactivity disorder.
    Kaplan G; Newcorn JH
    Pediatr Clin North Am; 2011 Feb; 58(1):99-120, xi. PubMed ID: 21281851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.